Abstract 572P
Background
Lung cancer was the leading cause of mortality in 2022, with 38.4% of patients having non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line treatment for EGFR-mutated NSCLC. A limited number of patients achieved five-year survival. This retrospective study aimed to provide real-world evidence and explore the factors affecting the five-year survival of patients with EGFR-mutated NSCLC.
Methods
This study included patients with EGFR-mutated NSCLC treated in Chang Gung Memorial Hospitals between 2011 and 2016, ensuring at least five years of follow-up or mortality. Odds ratios (ORs) were calculated using univariate and multivariate analyses. A scoring system based on a logistic regression model was designed to evaluate factor weightings on patients’ five-year survival. Their overall survival probability was estimated using the Kaplan-Meier model. The model’s accuracy was assessed using the area under the receiver operating characteristic curve (AUC).
Results
Of 1,873 enrolled patients, 185 were lost to follow-up within five years, leaving 1,787 for analysis. Of patients achieving five-year survival, more were female, age 65 years, had performance scores of 0∼1, no metastases, and adequate objective responses and disease control. A scoring system was developed by assigning points to each prognostic factor associated with increased risk of not achieving five-year survival: age > 65 years (1 point); performance score of 2∼4 (2 points); stage IV disease (1 point); liver (2 points), bone (1 point), or pleura (1 point) metastasis; and poor disease control (2 points). In the Kaplan-Meier model, the estimated five-year survival rate was 39.4%, 13.0%, 7.2%, and 2.2% for the low-risk (0∼1 point), intermediate-risk (2 points), high-risk (3 points), and very-high-risk (4∼10 points) groups, respectively. The prediction model’s AUC was 0.787 (95% CI: 0.752∼0.821), indicating fair accuracy.
Conclusions
We proposed a scoring system based on real-world data for predicting the five-year survival of patients with EGFR-mutated NSCLC treated with EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chang Gung Memorial Hospital (Linkou Branch).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract